Faricimab for High-frequent Aflibercept Treated Neovascular Age-related Macular Degeneration
Status:
COMPLETED
Trial end date:
2025-02-26
Target enrollment:
Participant gender:
Summary
Study purpose: To evaluate if previously high-frequent (3-5 weekly) aflibercept treated neovascular age-related macular degeneration (nAMD) can be extended in their treatment interval when switched to faricimab.
Primary objective: To assess the efficacy of faricimab compared to aflibercept in terms of durability at 32 weeks by extending treatment interval in previous high-frequent aflibercept treated nAMD.